TY - JOUR
T1 - Sex differences in outcomes of primary prevention implantable cardioverter-defibrillator therapy
T2 - combined registry data from eleven European countries
AU - Sticherling, Christian
AU - Arendacka, Barbora
AU - Svendsen, Jesper Hastrup
AU - Wijers, Sofieke
AU - Friede, Tim
AU - Stockinger, Jochem
AU - Dommasch, Michael
AU - Merkely, Bela
AU - Willems, Rik
AU - Lubinski, Andrzej
AU - Scharfe, Michael
AU - Braunschweig, Frieder
AU - Svetlosak, Martin
AU - Zürn, Christine S
AU - Huikuri, Heikki
AU - Flevari, Panagiota
AU - Lund-Andersen, Caspar
AU - Schaer, Beat A
AU - Tuinenburg, Anton E
AU - Bergau, Leonard
AU - Schmidt, Georg
AU - Szeplaki, Gabor
AU - Vandenberk, Bert
AU - Kowalczyk, Emilia
AU - Eick, Christian
AU - Juntilla, Juhani
AU - Conen, David
AU - Zabel, Markus
AU - EU-CERT-ICD Investigators
PY - 2018
Y1 - 2018
N2 - Aims: Therapy with an implantable cardioverter defibrillator (ICD) is established for the prevention of sudden cardiac death (SCD) in high risk patients. We aimed to determine the effectiveness of primary prevention ICD therapy by analysing registry data from 14 centres in 11 European countries compiled between 2002 and 2014, with emphasis on outcomes in women who have been underrepresented in all trials.Methods and results: Retrospective data of 14 local registries of primary prevention ICD implantations between 2002 and 2014 were compiled in a central database. Predefined primary outcome measures were overall mortality and first appropriate and first inappropriate shocks. A multivariable model enforcing a common hazard ratio for sex category across the centres, but allowing for centre-specific baseline hazards and centre specific effects of other covariates, was adjusted for age, the presence of ischaemic cardiomyopathy or a CRT-D, and left ventricular ejection fraction ≤25%. Of the 5033 patients, 957 (19%) were women. During a median follow-up of 33 months (IQR 16-55 months) 129 women (13%) and 807 men (20%) died (HR 0.65; 95% CI: [0.53, 0.79], P-value < 0.0001). An appropriate ICD shock occurred in 66 women (8%) and 514 men (14%; HR 0.61; 95% CI: 0.47-0.79; P = 0.0002).Conclusion: Our retrospective analysis of 14 local registries in 11 European countries demonstrates that fewer women than men undergo ICD implantation for primary prevention. After multivariate adjustment, women have a significantly lower mortality and receive fewer appropriate ICD shocks.
AB - Aims: Therapy with an implantable cardioverter defibrillator (ICD) is established for the prevention of sudden cardiac death (SCD) in high risk patients. We aimed to determine the effectiveness of primary prevention ICD therapy by analysing registry data from 14 centres in 11 European countries compiled between 2002 and 2014, with emphasis on outcomes in women who have been underrepresented in all trials.Methods and results: Retrospective data of 14 local registries of primary prevention ICD implantations between 2002 and 2014 were compiled in a central database. Predefined primary outcome measures were overall mortality and first appropriate and first inappropriate shocks. A multivariable model enforcing a common hazard ratio for sex category across the centres, but allowing for centre-specific baseline hazards and centre specific effects of other covariates, was adjusted for age, the presence of ischaemic cardiomyopathy or a CRT-D, and left ventricular ejection fraction ≤25%. Of the 5033 patients, 957 (19%) were women. During a median follow-up of 33 months (IQR 16-55 months) 129 women (13%) and 807 men (20%) died (HR 0.65; 95% CI: [0.53, 0.79], P-value < 0.0001). An appropriate ICD shock occurred in 66 women (8%) and 514 men (14%; HR 0.61; 95% CI: 0.47-0.79; P = 0.0002).Conclusion: Our retrospective analysis of 14 local registries in 11 European countries demonstrates that fewer women than men undergo ICD implantation for primary prevention. After multivariate adjustment, women have a significantly lower mortality and receive fewer appropriate ICD shocks.
KW - Aged
KW - Arrhythmias, Cardiac/complications
KW - Death, Sudden, Cardiac/epidemiology
KW - Defibrillators, Implantable/adverse effects
KW - Electric Countershock/adverse effects
KW - Equipment Failure/statistics & numerical data
KW - Europe/epidemiology
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Mortality
KW - Primary Prevention/methods
KW - Registries/statistics & numerical data
KW - Retrospective Studies
KW - Sex Factors
U2 - 10.1093/europace/eux176
DO - 10.1093/europace/eux176
M3 - Journal article
C2 - 29016784
VL - 20
SP - 963
EP - 970
JO - Europace
JF - Europace
SN - 1099-5129
IS - 6
ER -